BAX Pharma & Life Sciences

Patients ask AI.
AI answers without you.

Every day, millions of patients, caregivers, and HCPs ask ChatGPT and Gemini about treatments, drug efficacy, and brand alternatives. Not a single pharma company monitors this systematically.

Book an Executive Briefing → 2-month pilot — no commitment

Active pilots: Pharma · Biotech · MedTech · 3 slots available Q2 2026

pharma companies monitor AI brand mentions systematically

AI platforms audited simultaneously

life science sectors covered

<24h

to first calibrated report

Regulatory coverage: EU MDR · EMA Guidelines · FDA (21 CFR) · GDPR Art. 28 · GxP-aware · DORA (EU) 2022/2554

ICH Q10 · EMA/CHMP guidelines · EU Falsified Medicines Directive · NIS2 · Cloudflare EU

01 — Your sector

Select your category. See what AI says.

Each pharma segment faces a different AI visibility problem. Pick yours.

Patient query — ChatGPT, 11:43pm

"What's the difference between Humira and biosimilars for RA? Which is safer in 2026?"

For rheumatoid arthritis, adalimumab biosimilars (Hadlima, Cyltezo) offer equivalent efficacy to Humira at lower cost. Rinvoq and Xeljanz are JAK inhibitors — different mechanism, discuss with your rheumatologist. Your branded drug was not mentioned despite a comparable safety profile.

"We have the best post-marketing data in the category. AI sends patients to our biosimilar competitor."

BAX detects: your brand appears in 9% of treatment-decision queries. Biosimilar competitors dominate with 61% AI Share of Voice. Narrative gap: AI does not include your long-term safety data in responses.

Potential impact: ~22,000 monthly treatment queries in your indication

Consumer query — Gemini

"Best OTC painkiller for migraine that won't upset my stomach?"

For stomach-sensitive users, ibuprofen lysine (Nurofen Express) absorbs faster than standard ibuprofen. Paracetamol is gentler overall. Excedrin combines caffeine for migraine specifically. Your product was not included despite clinical evidence of GI tolerability.

"We invested $4M in a GI tolerability study. AI recommends our competitor based on older data."

BAX detects: AI consistently cites 2019 data for your category. Your 2024 tolerability study is not reflected in any AI platform. BAX identifies which platforms are most outdated and which queries to target first.

Potential impact: ~41,000 monthly OTC queries in your indication

HCP query — Perplexity

"Latest Phase III data for IL-17 inhibitors in psoriasis — which pipeline looks strongest?"

Novartis and Eli Lilly have the most robust Phase III data for IL-17 inhibition. AbbVie's Skyrizi shows strong durability data from PRIME studies. Your pipeline asset is not referenced despite positive interim data published in December 2025.

"HCPs use AI before prescribing. We're invisible at the exact moment of clinical decision."

BAX detects: your pipeline asset is absent from 94% of HCP-intent queries on Perplexity and Claude. BAX maps which data sources AI uses in your indication and provides a GEO strategy to close the gap.

Potential impact: ~7,800 monthly HCP-intent queries in your indication

Surgeon query — Claude

"Compare robotic surgical systems for colorectal procedures — Intuitive vs competitors 2026"

Intuitive Surgical's da Vinci remains the gold standard with the largest outcomes dataset. Medtronic Hugo is gaining traction in Europe with competitive CE marking. CMR Surgical's Versius shows promise for flexible port placement. Your system is not mentioned in comparative analyses.

"Procurement committees now come to demos already influenced by AI research. We need to be in that conversation."

BAX detects: your device appears in 3% of clinical comparison queries. Narrative frame analysis shows AI describes competitors with outcome data but describes your system with specifications only. BAX identifies the narrative gap and how to close it.

Potential impact: ~3,200 monthly HCP procurement queries in your category

02 — The problem

AI is influencing prescriptions.
Before patients reach your brand.

Rx & Biotech

Invisible at the treatment decision

A patient asks AI "which biologic for my condition?" — your drug is not in the answer. The question is asked before the first appointment. The decision is shaped before any HCP interaction.

BAX solves it: audits all 13 platforms in real-time for your indication queries, detects your AI Share of Voice, and shows exactly which clinical narratives are missing.

79% of patients research treatment options on AI before seeing a doctor

OTC & Consumer

Your R&D data doesn't reach AI

You funded clinical trials that prove superiority. AI doesn't know. It recommends your competitors based on data that is two, three, five years old. Your investment in evidence is invisible.

BAX solves it: identifies which AI platforms lag behind your evidence, maps the knowledge gap, and provides a GEO playbook to close it systematically.

AI models have a 12–18 month data lag for clinical trial outcomes

All segments

Wrong narrative — before you find out

AI might mention your brand — but with outdated safety language, incorrect contraindications, or competitive framing you cannot see or correct. A single wrong AI answer reaches millions of queries.

BAX solves it: Narrative Frame analysis monitors exactly how AI describes your product. Pharmacovigilance-aligned alerts fire when language deviates from approved labeling.

1 in 3 AI brand mentions in pharma contains a clinical inaccuracy

03 — How it works

Three steps. One day. Zero IT involvement.

15 minutes

Install & calibrate

Install the BAX Chrome extension. Configure your compound, indication, INN, brand name, competitors, and query templates. Pharma calibration covers patient, caregiver, and HCP personas separately.

No IT department. No API keys. No access to your systems.

4 hours

Audit 13 platforms

BAX queries all 13 AI platforms with your calibrated prompts across all three funnel stages: symptom awareness, treatment consideration, and brand decision. Results available same day.

Covers ChatGPT, Gemini, Perplexity, Claude, Copilot, Grok, and 7 others.

Next morning

Report & action plan

Branded PDF report with BAX Score, AI Share of Voice by indication, competitor benchmark, and prioritized GEO action plan. Pharmacovigilance alert log included.

Export to PDF, PPTX, XLSX. White-label available on Pro and Group.

04 — Plans & pricing

Three plans. One goal.

Veeva Vault PromoMats / Brandwatch: $8,000–20,000/mo · without AI monitoring or indication-level calibration

No risk

Pharma Pilot

For teams that need data before they commit

$3,500/mo

2 months only · full Pharma Pro access · zero obligation

1,000 credits / month

~5 full audits / month

Everything in Pharma Pro
NDA signed day 1
First audit within 24h
Zero obligation after pilot
Max. 3 pilots simultaneously

Start pilot →

★ Recommended

Pharma Pro

For pharma brands and biotech with 1–3 products

$7,500/mo

$250/day per seat · 10 seats

3,000 credits / month

~15 full audits / month

3 compounds + 20 competitors
All 13 AI platforms
Deep indication calibration
Patient + HCP persona sets
Narrative Frame analysis
Pharmacovigilance alert log
Weekly automated audits
PDF + PPTX + XLSX export
365-day history + trends
Dedicated account manager
Win/loss analysis
Real-time AI error alerts

Book a Demo →

Multi-brand

Pharma Group

For large pharma with multiple brands & TA teams

$16,500/mo

8,000 credits / month

~40 full audits / month

Unlimited brands & compounds
Unlimited competitors
All 13 AI platforms
Therapeutic area dashboards
White-label reports
Custom calibration per product
Pharmacovigilance package
API access
SLA + priority support
Medical affairs integration

Contact Sales →

Medical affairs asks. Do you have the AI data?

2-month pilot. Full platform access. No long-term commitment.

$3,500/mo

Start pilot →

Regulatory compliance from day one.

BAX is built for regulated industries. No external data transmission, no server-side storage, no access to client systems. All processing happens inside the browser. Complete legal package — DPA, SCC, risk assessment — so your compliance and legal teams can approve in days, not months. Pharma-specific: pharmacovigilance alert log included in all Pro and Group plans.

GDPR Art. 28 EU MDR 2017/745 EMA Guidelines DORA (EU) 2022/2554 NIS2 GxP-aware architecture Cloudflare EU Chrome MV3 ISO 27001 Q4 2026

Zero access to clinical systems. BAX never requests credentials to your safety database, eTMF, CTMS, or internal systems.
Data in EU only. All infrastructure runs on Cloudflare EU. No data leaves the European Economic Area.
Pharmacovigilance-aligned alerts. BAX flags when AI describes your drug with language that deviates from approved SmPC labeling. Logged and exportable.
Complete legal package. DPA, SCC, risk assessment, and vendor questionnaire — ready for your compliance team on day one.
Zero patient data. BAX queries public AI platforms with synthetic personas. It never touches patient records, prescriptions, or PII.

Next step

Your patients ask AI.
Do you know what it says?

The briefing takes 45 minutes. We bring the AI data for your indication. No preparation required on your side.

Book an Executive Briefing → Pilot $3,500/mo — no commitment

Sales hello@baxindex.com

Medical Affairs pharma@baxindex.com

Compliance security@baxindex.com

Patients ask AI. AI answers without you.